



AD-A211 966


Institute Report No. 398

PREKALLIKREIN AND PROTEASE INHIBITOR LEVELS IN
PLASMA FROM CONSCIOUS, HEMORRHAGED AND EUVOLEMIC
SWINE INFUSED WITH 7.5% NaCl/6% DEXTRAN-70

Michael A. Dubick, Ph.D.
and Charles E. Wade, Ph.D.

DIVISION OF MILITARY TRAUMA RESEARCH

July 1989



LETTERMAN ARMY INSTITUTE OF RESEARCH PRESIDIO OF SAN FRANCISCO CALIFORNIA 94129

DISTRIBUTION STATEMENT A

Approved for public release;
Distribution Unlimited

89 9 05 118

DTIC
ELECTE
SEP 07 1989
S B D


Prekallikrein and Protease inhibitor levels in plasma from conscious, Hemorrhaged and Euvoletic swine infused with 7.5% NaCl/6% Dextran-70, M.A. Dubick and C.E. Wade

Destroy this report when it is no longer needed. Do not return to the originator.

Citation of trade names in this report does not constitute an official endorsement or approval of the use of such items.

In conducting the research described in this report, the investigation adhered to the "Guide for the Care and Use of Laboratory Animals," as promulgated by the Committee on Revision of the Guide for Laboratory Animal Facilities and Care, Institute of Laboratory Animal Resources, National Research Council.

This material has been reviewed by Letterman Army Institute of Research and there is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the author(s) and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense. (AR 360-5)



Richard A. Kishimoto
COL, MSC
Acting Commander

8 Aug 89
(date)

This document has been approved for public release and sale; its distribution is unlimited.

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
1a. REPORT SECURITY CLASSIFICATION UNCLASSIFIED			1b. RESTRICTIVE MARKINGS		
2a. SECURITY CLASSIFICATION AUTHORITY			3. DISTRIBUTION / AVAILABILITY OF REPORT Approved for public release distribution is unlimited.		
2b. DECLASSIFICATION / DOWNGRADING SCHEDULE					
4. PERFORMING ORGANIZATION REPORT NUMBER(S) Institute Report No. 398			5. MONITORING ORGANIZATION REPORT NUMBER(S)		
6a. NAME OF PERFORMING ORGANIZATION Letterman Army Institute of Research		6b. OFFICE SYMBOL (If applicable) SGRD-ULT-M	7a. NAME OF MONITORING ORGANIZATION U.S. Army Medical Research and Development Command		
6c. ADDRESS (City, State, and ZIP Code) Division of Military Trauma Research, LAIR Presidio of San Francisco, CA 94129-6800			7b. ADDRESS (City, State, and ZIP Code) Ft. Detrick, Frederick, MD 21701		
8a. NAME OF FUNDING / SPONSORING ORGANIZATION		8b. OFFICE SYMBOL (If applicable)	9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER		
8c. ADDRESS (City, State, and ZIP Code)			10. SOURCE OF FUNDING NUMBERS		
			PROGRAM ELEMENT NO. 63807A	PROJECT NO. D826	TASK NO. AY
					WORK UNIT ACCESSION NO. 087
11. TITLE (Include Security Classification) (U) Prekallikrein and Protease inhibitor levels in plasma from conscious, Hemorrhaged and Euvolemic swine infused with 7.5% NaCl/6% Dextran-70.					
12. PERSONAL AUTHOR(S) M.A. Dubick and C.E. Wade					
13a. TYPE OF REPORT Institute		13b. TIME COVERED FROM _____ TO _____		14. DATE OF REPORT (Year, Month, Day) 890701	
15. PAGE COUNT 10					
16. SUPPLEMENTARY NOTATION					
17. COSATI CODES			18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)		
FIELD	GROUP	SUB-GROUP			
			HSD, Dextran, Hemorrhage, Swine, Prekallikrein,		
			Protease Inhibitors		
19. ABSTRACT (Continue on reverse if necessary and identify by block number) The kallikrein-kinin system can initiate a number of effects capable of further aggravating the effects of hemorrhage. The present study examines plasma prekallikrein concentrations and the levels and functional activity of circulating protease inhibitors known to bind kallikrein, in 5 euvolemic and 6 hemorrhaged swine infused with 7.5% NaCl/6% Dextran-70 (HSD). Pigs were hemorrhaged progressively over a 45 min period at 27 ml/kg body weight. HSD was then infused over a one (1) minute period into both groups of pigs at a dose of 4 ml/kg. Blood samples were withdrawn before, immediately after the hemorrhage period and at 5, 60 and 120 min following HSD infusion. Neither group of pigs showed significant changes in plasma prekallikrein concentrations in response to either hemorrhage or HSD infusion. In addition, plasma concentrations of α_1 -PI and α_2 -M and the functional activity of α_1 -PI were unaffected by hemorrhage or HSD. These data indicate that Dextran-70, when administered as HSD, is not an activator of the kallikrein-kinin system.					
20. DISTRIBUTION / AVAILABILITY OF ABSTRACT <input checked="" type="checkbox"/> UNCLASSIFIED/UNLIMITED <input type="checkbox"/> SAME AS RPT <input type="checkbox"/> DTIC USERS			21. ABSTRACT SECURITY CLASSIFICATION UNCLASSIFIED		
22a. NAME OF RESPONSIBLE INDIVIDUAL Dr. Michael A. Dubick			22b. TELEPHONE (Include Area Code) (415) 561-5816		22c. OFFICE SYMBOL SGRD-ULT-M

DD Form 1473, JUN 86

Previous editions are obsolete.

SECURITY CLASSIFICATION OF THIS PAGE

UNCLASSIFIED

Abstract

The kallikrein-kinin system can initiate a number of effects capable of further aggravating the effects of hemorrhage. The present study examines plasma prekallikrein concentrations and the levels and functional activity of circulating protease inhibitors known to bind kallikrein, in 5 euvoletic and 6 hemorrhaged swine infused with 7.5% NaCl/6% Dextran-70 (HSD). Pigs were hemorrhaged progressively over a 45 min period at 27 ml/kg body weight. HSD was then infused over a one (1) minute period into both groups of pigs at a dose of 4 ml/kg. Blood samples were withdrawn before, immediately after the hemorrhage period and at 5, 60 and 120 min following HSD infusion. Neither group of pigs showed significant changes in plasma prekallikrein concentrations in response to either hemorrhage or HSD infusion. In addition, plasma concentrations of α_1 -PI and α_2 -M and the functional activity of α_1 -PI were unaffected by hemorrhage or HSD. These data indicate that Dextran-70, when administered as HSD, is not an activator of the kallikrein-kinin system.

Accession For	
NTIS GRA&I	<input checked="checked" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By _____	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	

Prekallikrein and protease inhibitor levels in plasma from conscious, hemorrhaged and euvoletic swine infused with 7.5% NaCl/6% dextran-70 -- Dubick et al.

INTRODUCTION

A 7.5% NaCl/6% Dextran-70 solution (HSD) has recently been introduced for the management and treatment of hemorrhagic shock (1,2). Of the safety issues concerning the use of dextran solutions in humans (3-7), one area of attention focuses on the effects of dextran on hemostasis (4-7). In this regard dextran sulfate, at least in vitro, is a well known and potent activator of kallikrein activity (8) and this activation occurs at lower concentrations of dextran than those observed in plasma following its use for the treatment of hemorrhagic shock (9,10). Kallikrein is a serine protease found in serum and tissues. Under normal circumstances, the enzyme exists in plasma as prekallikrein and any active enzyme is usually bound and inactivated by α_2 -macroglobulin (α_2 M) (11). Activation of this enzyme system, leading to activation of bradykinin and the onset of a number of physiological responses (12) has been associated with different types of traumatic injury (13-15). Activation of the kallikrein-kinin system results in hypotension, natriuresis, arterial vasodilation, increased renal blood flow and a fall in peripheral resistance (12), effects directly opposed to the clinical objectives of HSD therapy for the treatment of hemorrhage. In addition, trauma and injury have been reported to lower plasma concentrations of α_2 -M and other protease inhibitors in both pigs and humans (16,17), and to activate prekallikrein (16). Thus, traumatic injury resulting in hemorrhage subsequently treated with HSD may result in potentiation of the actions of the kallikrein-kinin system.

Currently, little is known of dextran metabolism, when administered as HSD, for the treatment of hemorrhagic shock. Whether activation of the kallikrein cascade can occur with neutral dextrans or following their metabolism has not been addressed. The present study investigates plasma prekallikrein and protease inhibitor concentrations following HSD administration to euvoletic and hemorrhaged pigs.

MATERIALS AND METHODS

Animals and Experimental Protocol

Eleven immature (21.6 ± 0.6 kg) Yorkshire pigs (J.G. Boswell Co., Corcoran, CA) were randomly assigned to either the euvoletic (n=5) or hemorrhage (n=6) group. Animals were individually

housed in a common indoor laboratory holding facility with a 12 h light/dark cycle maintained at constant temperature and humidity, and fed a commercial chow and water, ad libitum. After a 1 to 3 week adaptation period to the laboratory environment, each pig was splenectomized and chronically instrumented with arterial and renal vein catheters and an abdominal aortic sideport catheter to remove blood during hemorrhage (18). A pyelostomy was also performed. Other aspects of the catheterization protocol and conditioning to the Pavlov sling have been detailed previously (19). All surgeries were performed under aseptic conditions, and the pigs were allowed to recover 5 days before the start of each experiment.

Following an 18 h fast, pigs were placed in the Pavlov sling and allowed to rest quietly until stable values for O_2 consumption were obtained. Two baseline blood and urine samples (time 0) were collected. Immediately thereafter, animals were hemorrhaged progressively at 27 ml/kg body weight over a 45 min period. The 6% Dextran[®]70/7.5% NaCl (HSD) solution (Pharmacia AB, Uppsala, Sweden; was then administered intravenously into the pulmonary artery at 4 ml/kg body weight over a 1 min period. Blood specimens were collected at the end of the hemorrhage or mock-hemorrhage period in euvoletic pigs, and at 15, 60, and 120 min following HSD infusion. This experimental protocol was designed to simulate conditions in which an injured person is brought to a hospital 2 h after injury for full resuscitation and replacement of lost blood.

Biochemical Assays

Plasma kallikrein activity was determined using H-D-prolyl-L-phenylalanyl-L-arginine-p-nitroanilide (S-2302) as substrate. Plasma samples were incubated with substrate solutions with or without prekallikrein activator at 37° C for 5 min and the absorbance read against a blank at 405 nm (20). Results were compared to a standard curve of kallikrein activity and data expressed as units/ml plasma.

Plasma concentrations of α_2 -macroglobulin (α_2 -M) and α_1 -protease inhibitor (α_1 -PI) were assessed by rocket immunoelectrophoresis according to the method of Laurell and McKay (21). In addition, plasma protease inhibitory capacity of α_1 -PI was determined as described by Dubick, et al. (22) using purified porcine pancreatic elastase and bovine trypsin as standards.

Statistical Considerations

Data were analyzed by 2-way ANOVA and analysis of covariance to evaluate the effects of HSD and time following infusion on

plasma kallikrein and protease inhibitor concentration and activities. A p value < 0.05 obtained by the Greenhouse-Geisser probability method was considered statistically significant.

RESULTS

The data indicate that neither hemorrhage nor HSD infusion significantly affected plasma prekallikrein concentrations in pigs (Table 1). In addition, essentially undetectable activated kallikrein activity was observed in both groups of pigs at all time points (data not shown).

Determination of the plasma protease inhibitory capacity of α_1 -PI, assayed as both trypsin and elastase inhibitory capacity, revealed no significant effects induced by HSD or hemorrhage (Table 1). Consequently, the ratio of elastase-to-trypsin inhibitory capacity did not change, thereby verifying the functional integrity of α_1 -PI. Determination of immunoreactive of α_1 -PI concentrations in plasma were found to be within normal limits and were not affected by hemorrhage nor HSD infusion (Table 1). In contrast, α_2 -M concentrations in plasma tended to be 10-20% lower in response to hemorrhage, but quickly returned to prehemorrhage levels following HSD infusion (Table 1).

DISCUSSION

Plasma prekallikrein is a key enzyme in activating bradykinin and regulating normal circulatory homeostasis (12). It has also been shown to regulate Factor XII-dependent activation of prorenin and inactivates the first component of complement (23). Endogenous substances such as Hageman Factor (Factor XII), in the intrinsic clotting cascade system, and enzymes such as trypsin and plasmin can activate prekallikrein to kallikrein (8,12,13). In addition, a number of exogenous substances can activate prekallikrein. Kaolin, ellagic acid and dextran-sulfate are among the more potent prekallikrein activators (8,24). Kluft (8) reported maximum activation with in vitro dextran-sulfate concentrations of 25 ug/ml, i.e., concentrations over 100-fold lower than peak dextran concentrations reported in plasma following HSD-infusion at doses of 4 ml/kg body weight (10). In the present study, the plasma concentrations of prekallikrein observed are in close agreement with those reported by others for normal individuals (25). In addition, the amidolytic assay employed has shown good correlation with previous assays and has been used successfully to monitor plasma prekallikrein activity in critically ill or multiple traumatized patients (14, 15). Since prekallikrein concentrations were not affected by HSD infusion in the present

study, and no significant activated kallikrein activity was detected, it appears that as a component of HSD, Dextran-70® is not an activator of the kallikrein-kinin system in euvolemic or hypovolemic swine. Although prekallikrein can be activated following trauma (15), the mechanisms responsible are not well understood. Potent activators of this system have been employed in vitro, and it is unknown to what extent these activators may be involved in the pathophysiology of prekallikrein activation. Nevertheless, since low concentrations of sulfates exist as anions in plasma, even a small potential for formation of dextran sulfate during the metabolism of HSD, could have dire consequence.

In plasma, kallikrein activity is inhibited by circulating protease inhibitors, particularly α_2 -M, C1-esterase inhibitor and α_1 -PI (8,23,24). The effectiveness of these inhibitors is illustrated by higher kallikrein activity in plasma incubated at 0°C than at 37°C (8,24). Although it has been reported that plasma levels of α_1 -PI and α_2 -M may be reduced following injury and trauma (16,17), the results from the present study do not indicate any significant effect of hemorrhage or HSD-infusion on α_1 -PI or α_2 -M concentrations in plasma. As indicated by a lack of change in the EIC-to-TIC ratio, the functional inhibitory capacity of α_1 -PI was also unaffected. It is known that the active site region of α_1 -PI can be oxidized under a variety of circumstances, resulting in a lower elastase inhibitory capacity and lower EIC-to-TIC ratio (26). For example, α_1 -PI can be oxidized by reactive oxygen compounds released by activated polymorphonuclear leukocytes (27). Although higher white blood cells have been observed in experimental animals infused with HSD (28), it does not appear that they have been activated, at least to a physiologically significant extent. Therefore, the data from the present study indicate that HSD administration to hemorrhaged or euvolemic pigs at the therapeutic dose of 4 ml/kg, does not activate prekallikrein or significantly affect plasma protease inhibitor concentrations or their function.

REFERENCES

1. Maningas PA, DeGuzman LR, Tillman FJ, Hinson CS, Priegnitz KJ, Volk KA, Bellamy RF. Small volume infusion of 7.5% NaCl in 6% Dextran 70 for the treatment of severe hemorrhagic shock in swine. *Ann Emerg Med* 1986;15:1131-1137.
2. Maningas PA, Bellamy RF. Hypertonic sodium chloride solutions for the prehospital management of traumatic hemorrhagic shock: A possible improvement in the standard of care? *Ann Emerg Med* 1986;15:1411-1414.
3. Hedin H, Richter W, Messmer K, Renck H, Ljungstrom K-G, Laubenthal H. Incidence, pathomechanism and prevention of dextran-induced anaphylactoid/anaphylactic reactions in man. *Develop Biol Stand* 1981;48:179-189.
4. Jacobaeus U. The effect of dextran on the coagulation of blood. *Acta Med Scand* 1955;151:505-507.
5. Aberg M, Hedner U, Bergentz S-E. The antithrombotic effect of dextran. *Scand J Haematol* 1979;34[Suppl]:61-68.
6. Miles LA, Rothschild Z, Griffin JH. Dextran sulfate-dependent fibrinolysis in whole human plasma. Dependence on factor XII and prekallikrein. *J Lab Clin Med* 1983;101:214-225.
7. Carlin G, Saldeen T. On the interaction between dextran and the primary fibrinolysis inhibitor α_2 -antiplasmin. *Thrombosis Res* 1980;19:103-110.
8. Kluft C. Determination of prekallikrein in human plasma: Optimal conditions for activating prekallikrein. *J Lab Clin Med* 1978;83-95.
9. Kramer GC, Walsh JC, Perron PR, Gunther RA, Holcroft JW. A comparison of hypertonic saline/dextran versus hypertonic saline/hetastarch for resuscitation of hypovolemia. *Brazilian J Med Biol Res* 1989;22:279-282.
10. Summary JJ, Dubick MA, Ryan BA, Loveday JA, Gonzaludo GA, Wade CE. Dextran concentrations following administrations of 7.5% NaCl/6% dextran to euvoletic or hypovolemic pigs. *FASEB J* 1989;3:A713.
11. Barrett AJ. α_2 -Macroglobulin. *Methods Enzymol* 1981;80:737-754.

12. Sharma JN. Interrelationship between the kallikrein-kinin system and hypertension: A review. *Gen Pharmacol* 1988;19:177-187.
13. Ryan JW, Moffat JG, Thompson AG. Role of bradykinin system in acute hemorrhagic pancreatitis. *Arch Surg* 1965;91:14-24.
14. Kierulf P, Aasen AO, Aune S, Godal HC, Ruud TE, Vaage J. Chromogenic peptide substrate assays in patients with multiple trauma. *Acta Chir Scand [Suppl]* 1982;509:69-72.
15. Kalter ES, Vlooswijk RAA, Bouma BN. Determination of prekallikrein using an amidolytic assay in plasma samples of critically ill patients. *Acta Chir Scand [Suppl]* 1982;509:43-47.
16. Fleck A. Acute phase response: Implications for nutrition and recovery. *Nutrition* 1988;4:109-117.
17. Svendsen J, Westrom BR, Svendsen LS, Bengtsson A-C, Ohlsson B, Karlsson BW. Some blood serum characteristics of newborn, unaffected pigs and of pigs dying within the perinatal period: Stillborn, intrapartum pigs, weakborn pigs, underweight pigs and traumatized pigs. In: Tumbleson ME, ed. *Swine in Biomedical Research; vol 2*. New York: Plenum Press, 1986;1277-1288.
18. Traverso LW, Moore CC, Tillman FJ. A clinically applicable exsanguination shock model in swine. *Circ Shock* 1984;12:1.
19. Wade CE, Hannon JP, Bossone CA, Hunt MM, Rodkey WG. Cardiovascular and hormonal responses of conscious pigs during physical restraint. In: Tumbleson ME, ed. *Swine in Biomedical Research 3*; New York, Plenum Press, 1986;1395-1404.
20. Claeson G, Friberger P, Knos M, Eriksson E. Methods for determination of prekallikrein in plasma, glandular kallikrein and urokinase. *Haemostasis* 1978;7:76-78.
21. Laurell CB, McKay EJ. Electroimmunoassay. *Methods Enzymol* 1981;74:272-290.
22. Dubick MA, Mayer AD, Majumdar APN, Mar G, McMahon MJ, Geokas MC. Biochemical studies in peritoneal fluid from patients with acute pancreatitis. Relationship to etiology. *Dig Dis Sci* 1987;32:305-312.
23. Silverberg M, Kaplan AP. Prekallikrein. *Methods Enzymol* 1988;163:85-95.

24. Amundsen E, Gallimore MJ, Aasen AO, Larsbraaten M, Lyngaas K. Activation of human plasma prekallikrein: Influence of activators, activation time and temperature and inhibitors. *Thromb Res* 1987;13:625-636.
25. Fisher CA, Schmaier AH, Addonizio VP, Colman RW. Assay of prekallikrein in human plasma: Comparison of amidolytic, esterolytic, coagulation and immunochemical assays. *Blood* 1982;59:963-970.
26. Beatty K, Robertie P, Senior RM, Travis J. Determination of oxidized alpha-1-proteinase inhibitor in serum. *J Lab Clin Med* 1982;100:186-192.
27. Carp H, Janoff A. In vitro suppression of serum elastase-inhibitory capacity by reactive oxygen species generated by phagocytosing polymorphonuclear leukocytes. *J Clin Invest* 1979;63:793-797.
28. Ryan BA, Summary JJ, Dubick MA, Bowman PD, Wilson L, Wade CE. The hemostatic and hematologic effects of hypertonic saline (7.5%) Dextran-70 (HSD) in swine and rabbits. *FASEB J* 1989;3:A1210.

Table 1

Prekallikrein and Protease Inhibitors in Plasma from
Euvoletic (E) and Hemorrhaged (H) Swine Infused with HSD

		Time (min)			
		0	5	60	120
Group					
Prekallikrein (U/dl)	E	130±43(4)	137±37(4)	148±34(4)	160±34(4)
	H	136±45(5)	125±47(4)	140±40(4)	161±46(4)
α_1 - PI ² (mg/dl)	E	295±19(5)	298±20(5)	297±17(5)	296±12(5)
	H	285±12(6)	276±15(5)	287±18(5)	310±18(5)
α_2 -M ³ (mg/dl)	E	344±16(5)	352±11(5)	353±22(5)	320±20(5)
	H	320±18(6)	336±27(5)	371± 8(5)	369±5(5)
TIC ⁴ (% inhibition/ 20 μ l)	E	47.8±4.8(4)	51.0±3.4(4)	51.0±5.9(4)	48.8±8.4(3)
	H	57.8±4.0(6)	53.0±6.8(3)	59.7±2.7(6)	59.6±3.9(6)
EIC ⁵ (% inhibition/ 20 μ l)	E	84.4±1.4(4)	86.0±1.1(4)	85.3±1.1(4)	87.0±2.1(3)
	H	85.1±1.1(6)	85.7±0.1(6)	86.3±0.5(6)	86.0±0.8(6)
EIC/TIC Ratio	E	1.82±0.18(4)	2.07±0.29(4)	2.06±0.21(4)	2.37±0.34(3)
	H	1.52±0.11(6)	1.68±0.23(3)	1.47±0.07(6)	1.47±0.10(6)

¹Data expressed as mean ±S.E.(n)

² α_1 -Protease inhibitor

³ α_2 -macroglobulin

⁴Trypsin inhibitory capacity

⁵Elastase inhibitory capacity

OFFICIAL DISTRIBUTION LIST

Commander
US Army Medical Research
& Development Command
ATTN: SGRD-RMS/Mrs. Madigan
Fort Detrick, MD 21701-5012

Defense Technical Information Center
ATTN: DTIC/DDAB (2 copies)
Cameron Station
Alexandria, VA 22304-6145

Office of Under Secretary of Defense
Research and Engineering
ATTN: R&AT (E&LS), Room 3D129
The Pentagon
Washington, DC 20301-3080

DASG-AAFJML
Army/Air Force Joint Medical Library
Offices of the Surgeons General
5109 Leesburg Pike, Room 670
Falls Church, VA 22041-3258

HQ DA (DASG-ZXA)
WASH DC 20310-2300

Commandant
Academy of Health Sciences
US Army
ATTN: HSHA-CDM
Fort Sam Houston, TX 78234-6100

Uniformed Services University of
Health Sciences
Office of Grants Management
4301 Jones Bridge Road
Bethesda, MD 20814-4799

US Army Research Office
ATTN: Chemical and Biological
Sciences Division
PO Box 12211
Research Triangle Park, NC 27709-2211

Director
ATTN: SGRD-UWZ-L
Walter Reed Army Institute of Research
Washington, DC 20307-5100

Commander
US Army Medical Research Institute
of Infectious Diseases
ATTN: SGRD-ULZ-A
Fort Detrick, MD 21701-5011

Commander
US Army Medical Bioengineering Research
and Development Laboratory
ATTN: SGRD-UBG-M
Fort Detrick, Bldg 568
Frederick, MD 21701-5010

Commander
US Army Medical Bioengineering
Research & Development Laboratory
ATTN: Library
Fort Detrick, Bldg 568
Frederick, MD 21701-5010

Commander
US Army Research Institute
of Environmental Medicine
ATTN: SGRD-UE-RSA
Kansas Street
Natick, MA 01760-5007

Commander
US Army Research Institute of
Surgical Research
Fort Sam Houston, TX 78234-6200

Commander
US Army Research Institute of
Chemical Defense
ATTN: SGRD-UV-AJ
Aberdeen Proving Ground, MD 21010-5425

Commander
US Army Aeromedical Research
Laboratory
Fort Rucker, AL 36362-5000

AIR FORCE Office of Scientific
Research (NL)
Building 410, Room A217
Bolling Air Force Base, DC 20332-6448

USAF School of Aerospace Medicine
Document Section
USAFSAM/TSKD
Brooks Air Force Base, TX 78235-5301

Head, Biological Sciences Division
OFFICE OF NAVAL RESEARCH
800 North Quincy Street
Arlington, VA 22217-5000

Commander
Naval Medical Command-02
Department of the Navy
Washington, DC 20372-5120